IONS Ionis Pharmaceuticals Inc

P/E --
Forward P/E 90.91
Price/Sales 10.65
Beta 0.419
Div Yield --
Market Cap --

Company Analysis

Latest News

Ionis Lost Its Biggest Bet on Heart Disease — Can Its Remaining Pipeline Justify the Stock?

Ionis Lost Its Biggest Bet on Heart Disease — Can Its Remaining Pipeline Justify the Stock?

Shares of Ionis Pharmaceuticals continued their slide Monday, trading at $53.73 — down 7.5% on the day and roughly 37% below their ~$86 level before the July 9...

🔴 Ionis Pharmaceuticals is trading 7.5% down today after pelacarsen trial failure compounds earlier setbacks

Ionis Pharmaceuticals is trading 7.5% down now at $53.73. This decline is primarily driven by the continued market reaction to the recent failure of the Phase...

🔴 Ionis Pharmaceuticals is trading 11.5% down in pre-market after CARDIO-TTRansform failed its primary endpoint

Ionis Pharmaceuticals is trading 11.5% down at $51.40, with the decline appearing to extend pressure from the July 9 announcement that the Phase 3...

Ionis' Partnered Drug Pelacarsen Fails to Meet Primary Endpoint in Phase 3 Study

Ionis' Partnered Drug Pelacarsen Fails to Meet Primary Endpoint in Phase 3 Study

Ionis Pharmaceuticals announced that its partner, Novartis, reported that the Phase 3 Lp(a)HORIZON study for the drug pelacarsen did not meet its primary...

🔴 Ionis Pharmaceuticals is trading 13% down in after-hours trading despite FDA approval of ZANVASTRO

Ionis Pharmaceuticals is trading 12.55% down at $50.80, after closing at $58.09 on September 4, 2026; the decline follows FDA approval of ZANVASTRO for...

Ionis Pharmaceuticals Receives FDA Approval for ZANVASTRO™ for Alexander Disease

Ionis Pharmaceuticals Receives FDA Approval for ZANVASTRO™ for Alexander Disease

Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease...

🔴 Ionis Pharmaceuticals is trading 4.8% down today without a new company-specific catalyst

Ionis Pharmaceuticals is trading at $58.39, down 4.79%, without a new company-specific catalyst identified for September 3, 2026. - Ionis’s...

🔴 Ionis Pharmaceuticals is trading 4.2% down in pre-market — no clear company-specific catalyst identified

Ionis Pharmaceuticals is trading 4.2% down at $58.75 after closing at $61.33 on September 2, 2026; no clear company-specific catalyst was identified. - Ionis...

🔴 Ionis Pharmaceuticals is trading 4.23% down in after-hours trading with no clear company-specific catalyst identified

Ionis Pharmaceuticals is trading 4.23% down at $58.74 after closing at $61.34 on September 2, 2026, with no clear company-specific catalyst identified. - No...